Utility of Direct Adventitial Delivery of Dexamethasone to Prevent Restenosis - DANCE and LIMBO Studies - George Adams, MD, MHS

↳ This is a section part of Moment: CRT 2016 Technology & Innovation - New Stent Platforms and Local Drug Delivery

Add this Moment to your Passport

Learn from this moment and keep it forever.

Add To Passport

$6.99

This moment is included in Simple Premium - Get started for free.

FREE with Simple Premium

Start your 30-day free trial

Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Preview

Summary

Utility of Direct Adventitial Delivery of Dexamethasone to Prevent Restenosis - DANCE and LIMBO Studies presented by George Adams, MD, MHS at CRT 2016

Add this Moment to your Passport

Learn from this moment and keep it forever.

Add To Passport

$6.99

This moment is included in Simple Premium - Get started for free.

FREE with Simple Premium

Start your 30-day free trial

Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Target Audience

Interventional Cardiologists
Interventional Fellows

Session Name: New Stent Platforms and Local Drug Delivery

Track: Technology & Innovation

Learning Objectives

Update in advances with bioresorbable & DCB technologies in interventional procedures

Other Components in this Moment

Overview

Utility of Direct Adventitial Delivery of Dexamethasone to Prevent Restenosis - DANCE and LIMBO Studies - George Adams, MD, MHS

Local Drug Delivery Primer for PAD - Sahil Parikh, MD, FSCAI

Micro-engineered Grooved Stent Surfaces and Beyond: Technology Description and Preliminary Data - Juan Granada, MD

How Can We Improve the Current Stent Technology? - Michael Joner, MD